Hormone therapy in epithelial ovarian cancer

Endocrine-Related Cancer

Volumn 7, Issue 2, 2000, Pages 85-93

  Makar, A P ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GONADORELIN ANTAGONIST; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; HYDROCORTISONE; MIFEPRISTONE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN;

CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; FEMALE; HORMONE DEPENDENCE; HUMAN; OVARY CANCER; POSTMENOPAUSE; REVIEW;

EID: 0033867902     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070085     Document Type: Review

References (100)

1. Abraham GE, Lobotsky J & Lioyd CW 1969 Metabolism of testosterone and androstenedione in normal and ovariectomized women. Journal of Clinical Investigation 48 696-703.
2. Adami AO, Bergström R, Persson I & Sparén P 1990 The incidence of ovarian cancer in Sweden 1960-1984. American Journal of Epidemiology 132 446-452.
3. Adelson MD & Recce MT 1993 Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors. Clinical Obstetrics and Gynecology 36 690-700.
4. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D & Fryer JG 1993 Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase III trials of the mid-atlantic oncology program. Journal of Clinical Oncology 11 1957-1968.
5. Amin W, Karlan BY & Littlefield BA 1987 Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth and morphological alterations. Cancer Research 47 6040-6045.
6. Bäkström T, Mählck CG & Kjellgren O 1983 Progesterone as a possible tumor marker for 'non-endocrine' ovarian malignant tumors. Obstetrics and Gynecology 16 129-138.
7. Beecham J, Blessing J, Creasman W & Hatch K 1987 The role of tamoxifen as second line therapy in advanced ovarian cancers evaluated for receptor status and tumor grade. Proceedings of the International Gynecological Cancer Society 1 117.
8. Belinson JL, McClure M & Badger G 1987 Randomized trial of megestrol acetate vs megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecology and Oncology 28 151-155.
9. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinne GR, Soper JT, Dodge R, Clarck Pearson & Merks P 1990 Over-expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Research 50 4087-4091.
10. Bergquist A, Kullander S & Thorell J 1981 A study of oestrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors treated with medroxy progesterone acetate. Acta Obstetrica et Gynaecologica Scandinavica 101 75-81.
11. Bruckner HW & Motwani BT 1989 Treatment of advanced refractory ovarian carcinoma with a gonadotropin releasing hormone analogue. American Journal of Obstetrics and Gynecology 161 1216-1218.
12. Burger CW, van Doom HC, van der Valk P & Bonfrèr HMG 1999 Oestrogen, progesterone and androgen receptors in ovarian neoplasm; correlation between immunohistochemical and biochemical receptor analysis. International Journal of Gynecological Cancer 9 17.
13. Caldas C & McGuire WP III 1995 Paclitaxel (taxol) therapy in ovarian carcinoma. Seminars in Oncology 20 50-56.
14. Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Kullander S, Kauppila A, Ayalon D, Serially A & Oberheuser F 1996 Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. Cancer 78 1452-1460.
15. Ercoli A, Scambia G, Fattorossi A, Paspaglio G, Battaglia A, Cicchillitti L, Malorni W, Rainaldi G, Benedetti P & Mancuso S 1998 Comparative study of the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor negative ovarian cancer cell line. International Journal of Cancer 76 47-54.
16. Erickson LD, Hartmann LC, Su JQ, Nielsen SNJ, Pfeifel DM, Goldberg RM, Levitt R & Stanope CR 1994 Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. Gynecology and Oncology 54 196-200.
17. Falkson CI, Falkson HC & Falkson G 1996 Cisplatin versus cisplatin plus d-Trp-6LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of GnRH analogue to cisplatin. Oncology 53 313-317.
18. Fathalla MF 1971 Incessant ovulation - a factor in ovarian neoplasia? Lancet ii 163.
19. Franceschi S 1989 Reproductive factors and cancers of the breast, ovary and endometrium. European Journal of Cancer and Clinical Oncology 25 1933-1943.
20. From GL, Freedman RS, Fritsche HA, Atkinson EN & Scott W 1991 Sequentially administered ethinyl and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer 68 1885-1889
21. Galli MC, De Giovanni C & Nicoletti G, Grilli S, Nanni P, Prodi G et al. 1981 The occurrence of multiple steroid hormone receptors in disease free and neoplastic human ovary. Cancer 47 1297-1302.
22. Galtier-Dereure F, Capony F, Maudelonde T & Rochefort H 1992 Estradiol stimulates cell growth and secretion of precathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. Journal of Clinical Endocrinology and Metabolism 75 1497-1502.
23. Geisenger KR, Kutte TE, Pettenati MJ, Welander CE, Dennard Y, Collins LA & Berens ME 1989 Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 63 280-288.
24. Geisler H 1983 Megestrol acetate for the palliation of advanced ovarian carcinoma. Obstetrics and Gynecology 61 95-98.
25. Geisler H 1985 The use of high-dose megestrol acetate in the treatment of ovarian cancer. Seminars in Oncology 11 20.
26. Greenblatt RB, Colle ML & Mahesh VB 1976 Ovarian and adrenal steroid production in the postmenopausal woman. Obstetrics and Gynecology 47 383-387.
27. Grodin JM, Siiteri PK & MacDonald PC 1973 Source of estrogen production in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 36 207-214.
28. Guidozzi F & Paponte A 1999 Estrogen replacement therapy in ovarian cancer survivors. International Journal of Gynecological Cancer 9 4.
29. Gwin ML, Lee N, Rhodes PH, Layde PM & Rubin G 1989 Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. Journal of Clinical Epidemiology 43 559-568.
30. Hamilton TC, Behrens BC, Louie KG & Ozols RF 1984 Induction of progesterone receptor in human ovarian cancer. Journal of Clinical Endocrinology and Metabolism 59 561-563.
31. Harding M, Cowan S, Hole D, Cassidy L, Kitchener H, Davis J & Leake R 1990 Estrogen and progesterone receptors in ovarian cancer. Cancer 65 486-491.
32. Hua W, Christianson T, Roougoet C, Rochefort H & Clinton G 1995 SKOV3 ovarian carcinoma cells have functional estrogen receptors but are growth resistant to estrogen and antiestrogens. Journal of Steroid Biochemistry and Molecular Biology 55 279-289.
33. Iversen OE 1988 Prognostic value of flow cytometric DNA index in human ovarian cancer. Cancer 61 971-975.
34. Jäger W, Sauerbrei W, Beck E, Maasen V, Stumpfe M, Meier W, Kunh W & Jänicke F 1995 A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Research 15 2639-2642.
35. Jakobsen A, Bertelsen K & Sell A 1987 Cyclic hormonal treatment in ovarian cancer. A phase II trial. European Journal of Cancer and Clinical Oncology 23 915-916.
36. Jolles CJ, Freedman RS & Jones LA 1983 Estrogen and progesterone therapy in advanced ovarian cancer: preliminary report. Gynecology and Oncology 16 352-359.
37. Judd HL, Judd GE, Lucas WE & Yen SSC 1974a Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. Journal of Clinical Endocrinology and Metabolism 39 1020-1024.
38. Judd HL, Lucas WE & Yen SSC 1974b Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. American Journal of Obstetrics and Gynecology 118 793-798.
39. Kaern J, Tropé CG, Kjørstad KE, Abeler V & Pettersen EO 1990 Cellular DNA contents as a new prognostic tool in patients with borderline tumors of the ovary. Gynecology and Oncology 38 452-457.
40. Karlan BY, Amin W, Casper SE & Littlefield BA 1988 Hormonal regulation of CA 125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids. Cancer Research 48 3502-3506.
41. Kavanagh JJ, Wharton JT & Roberts WS 1987 Androgen therapy in the treatment of refractory epithelial ovarian cancer. Cancer Treatment Report 71 537-538.
42. Kavanagh JJ, Roberts W, Townsend P & Hewitt S 1989 Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. Journal of Clinical Oncology 7 115-118.
43. Kikuchi Y, Hirata J, Kita T, Imaizumi E, Tode T & Nagata I 1993 Enhancement of antiproliferative effect of cis-diaminedichloro-platinum (II) by clomiphene and tamoxifen in human ovarian cancer cells. Gynecology and Oncology 49 365-372.
44. Kyrwicki RF, Figueroa JA, Jacjson JC, Wozelsky TW, Shimasaki S, von Hoff DD & Yee D 1993 Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. European Journal of Cancer 29A 2015-2019.
45. Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF & Miller WR 1994a Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. European Journal of Cancer 30A 682-686.
46. Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF & Miller WR 1994b The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. Journal of Steroid Biochemistry and Molecular Biology 50 131-135.
47. Long RTL & Evans AM 1963 Diethylstilbestrol as a chemotherapeutic agent for ovarian cancer. Modern Medicine 60 1125-1127.
48. McClay EF, Albright KD, Jones JA, Christen RD & Howell SB 1994 Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. British Journal of Cancer 70 449-452.
49. Mählck CG 1986 Plasma steroid hormones in women with epithelial ovarian carcinoma. Doctoral thesis. Acta Obstetrica et Gynecologica Scandinavica (Suppl) 137 1-32.
50. Makar AP 1995 Prognostic studies in cancer of the ovary and fallopian tube with emphasis on the CA 125 and c-erbB-2 oncogene. Summary of doctoral thesis. Acta Obstetrica et Gynecologica Scandinavica 74 238-240.
51. Makar AP, Kristensen GB, Nesland J, Bormer OP & Tropé CG 1994 The expression of c-erbB-2 (HER-2/neu) oncogene in patients with invasive ovarian malignancies. International Journal of Gynecological Cancer 4 194-199.
52. Makar AP, Baeklandt M, Tropé CG & Kristensen GB 1995 The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO stage III ovarian cancer. Gynecology and Oncology 56 175-180.
53. Mant JWF & Vessey MP 1995 Mortality trends in ovarian cancer. In Epithelial Cancer of the Ovary, edn 1, pp 1-12. Eds FG Lawton, JP Neijt & KD Swenerton. London: BMJ Publishing Group.
54. Marinaccio M, D'Addario VD, Serrati A, Pinto V & Gagnazzo G 1996 Leuprolide acetate as a salvage therapy in relapsed epithelial ovarian cancer. European Journal of Clinical Oncology 17 286-288.
55. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W & Dubeshter B 1996 Tamoxifen in platinum refractory ovarian cancer. A Gynecologic Oncology Group ancillary report. Gynecology and Oncology 62 4-6.
56. Marth C, Sorheim N, Kaern J & Tropé C 1997 Tamoxifen in the treatment of recurrent ovarian carcinoma. Internationl Journal of Gynecological Cancer 7 256-261.
57. Miller WR & Langdon SP 1997 Steroid hormones and cancer: (II) lessons from experimental system. European Journal of Surgical Oncology 23 72-83.
58. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K & Armatis P 1997 Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. Journal of the National Cancer Institute 89 1803-1809.
59. Mosgaard BJ, Lidegaard O & Andersen AN 1997 The impact of parity, infertility and the treatment with fertility drugs on the risk of ovarian cancer. Acta Obstetrica et Gynaecologica Scandinavica 76 89-95.
60. Myers AM, Moore GE & Major FJ 1981 Advanced ovarian carcinoma: response to antiestrogen therapy. Cancer 48 2368-2370.
61. Nash J, Hall L, Ozols R, Young R, Smyth J & Hamilton T 1989a Estrogenic regulation and growth factor expression in human ovarian cancer in vitro. Proceedings of the American Assocaition for Cancer Research 30 1189.
62. Nash JD, Ozols RF, Smyth JF & Hamilton TC 1989b Estrogen and antiestrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstetrics and Gynecology 73 1009-1016.
63. Neijt JP 1995 Optimum chemotherapy regimens, dose intensity, and new drugs. In Epithelial Cancer of the Ovary, edn 1, pp 186-209. Eds FG Lawton, JP Neijt & KD Swenerton. London: BMJ Publishing Group.
64. O'Brien TJ, Hemandez W, Jernstrom PJ, Seymour BD, Morrow CP & Sykes JA 1981 Modulation of protein expression in endometrial carcinoma cells by in vitro exposure to estradiol and progesterone. American Journal of Obstetrics and Gynecology 139 67-72.
65. Parazzini F, La Vecchia C, Negri E & Gentile A 1989 Menstrual factors and the risk of epithelial ovarian cancer. Journal of Clinical Epidemiology 5 443-448.
66. Parazzini F, Neggri E, La Vecchia C, Moroni S, Franceschi S & Crosignani PG 1997 Treatment of infertility and risk of invasive epithelial ovarian cancer. Human Reproduction 12 2159-2161.
67. Parkin MD 1989 Cancers of the breast, endometrium, and ovary: geographic correlations. European Journal of Cancer and Clinical Oncology 25 1917-1925.
68. Parmar H, Philips RH, Rustin G, Lightman SL & Shally AV 1988 Therapy of advanced ovarian cancer with d-Trp-6-LH-RH (decapeptyl) microcapsules. Biomedicine and Pharmacotherapy 42 531-538.
69. Peterson CM & Zimniski SJ 1990 A long-acting gonadotropin releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstetrics and Gynecology 76 264-267.
70. Peterson CM, Jolles CJ, Carrell DT, Straight RC, Jones KP, Poulson AM Jr & Hatasaka H 1994 GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) hetero-transplanted in the nude mouse is characterized by latency and transience. Gynecology and Oncology 52 26-30.
71. Pettersson F 1994 Annual Report on the Result of Treatment in Gynecological Cancer. Stockholm, Sweden: FIGO 22 83-102.
72. Rendina GM, Donadio C & Giovannini M 1982 Steroid receptors and progestin therapy in ovarian endometrioid carcinoma. European Journal of Gynaecological Oncology 3 241-246.
73. Risch HA, Weiss NH & Lyon JL 1983 Events of reproductive life and the incidence of epithelial ovarian cancer. American Journal of Epidemiology 117 1128-1139.
74. Romagnolo D, Annab LA, Risinger JL, Terry LA, Lyon TT & Barrett JC 1996 Regulation of expression of BRCA-1 cancer cells. Proceedings of the American Assocaition for Cancer Research 37 516.
75. Rose FV & Barnea ER 1996 Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12 999-1003.
76. Rothschild N, Gray R, Smith L, Matelski H & Ahlgren J 1987 Phase II study aminoglutethimide in advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology 6 115.
77. Scambia G, Benedetti Panici P, Greggi S, Baiocchi G, Perrone L & Mancuso S 1990 Phase II study with an LH-RH analog in advanced ovarian cancer. Journal of Gynecology and Endocrinology VI 5-7.
78. Schwartz PE, Keating G, MacLusky N, Naftolin F & Eisenfeld A 1982 Tamoxifen therapy for advanced ovarian cancer. Obstetrics and Gynecology 59 583-588.
79. Schwartz PE, Chambers JT, Kohom EL, Chambers SK, Weitzman H, Voynick JM et al. 1989 Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. Cancer 63 1074-1078.
80. Sevelda P, Denison U, Schemper M, Spona J, Varva N & Salzer H 1990 Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. British Journal of Obstetrics and Gynecology 97 706-712.
81. Shirley DR, Kavanagh JJ, Gershenson DM, Freedman RS, Copeland LJ & Jones LA 1985 Tamoxifen therapy for epithelial ovarian cancer. Obstetrics and Gynecology 66 575-578.
82. Sikic BI, Scudder SA, Ballon SC, Soriero OM, Christman JE, Suey L et al. 1986 High dose megestrol acetate therapy of ovarian carcinoma; a phase II study by the Northern California Oncology Group. Seminars in Oncology 4 26-32.
83. Simons WE, Albrecht M, Hansel M, Dietl M & Holzel F 1983 Cell line derived from human ovarian carcinomas: growth stimulation by gondotropic and steroid hormones. Journal of the National Cancer Institute 70 839-845.
84. Simpson BJB, Rabiaz GJ, Macloed KG, Hirst GL, Miller WR & Langdon SP 1996 Estrogen regulation of TGFa in ovarian cancer. Proceedings of the American Association for Cancer Research 37 224.
85. Slevin ML, Harvey VJ, Osborne RJ, Shepherd JH, Williams CJ & Mead GM 1986 A phase II study of tamoxifen in ovarian cancer. European Journal of Cancer and Clinical Oncology 22 309-312.
86. Slotman BJ & Rao BR 1988 Ovarian cancer (review): etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Research 8 417-434.
87. Smith LH & Oi RH 1984 Detection of malignant ovarian neoplasms: a review of the literature. I Detection of the patient at risk; clinical, radiological and cytological detection. Obstetrical and Gynecological Survey 39 313-328.
88. Sutton GP, Senior MB & Strauss JF 1986 Estrogen- and gestagenen in epithelial ovarian malignancies. Gynecology and Oncology 23 176-182.
89. Thigpen JT, Vance RB, Balducci L & Khansur T 1984 New drugs and experimental approaches in ovarian cancer treatment. Seminars in Oncology 11 314-326.
90. Tropé CG & Makar AP 1991 Epidemiology, etiology, screening, prevention, and diagnosis in female genital cancer. Current Opinion in Oncology 3 909-919.
91. Tropé C, Johnsson JE, Sigurdsson K & Simonse E 1982 High-dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma. Cancer Treatment Reviews 66 1441-1443.
92. Van Der Vange N, Greggi S, Burger W, Kenemans P & Vermorken JB 1995 Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncologica 34 813-820.
93. Van Der Velden J, Gitsch G, Wain GV, Friedlander ML & Hacker NF 1995 Tamoxifen in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer 5 301-305.
94. Van Leeuwen FE & Rookus MA 1989 The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. European Journal of Cancer and Clinical Oncology 25 1961-1972.
95. Weiner SA, Alberts DS, Surwit EA, Davis J & Grosso D 1987 Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecology and Oncology 27 208-213.
96. Whittemore AS 1993 Fertility drugs and risk of ovarian cancer. Human Reproduction 8 999-1000.
97. Whittemore AS, Harris R & Itnyre J 1992 Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV The pathogenesis of epithelial ovarian cancer. American Journal of Epidemiology 136 1212-1220.
98. Wilailak S, Linasmita V, Srisupundit S, Tangtrakul S, Bullangpoti S & Israngura N 1999 Phase II study of megestrol acetate in patients with refractory epithelial ovarian cancer. International Journal of Gynaecological Cancer 9 12.
99. Wu Ml, Whittemore AS, Paffenbarger JR, Sarles DL, Kampert JB, Grosser S et al. 1988 Personal and environmental characteristics related to epithelial ovarian cancer in reproductive and menstrual events and oral contraceptive use. American Journal of Epidemiology 6 1216-1227.
100. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K & Schally AV 1994 Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proceedings of the National Academy of Sciences of the USA 91 7090-7094.